Humana Covers BlueWind Tibial Neuromodulation Across 11 Million Medicare Advantage Members

Medtronic plc reported 13.7% organic and reported topline growth in its first quarter, with revenue reaching $9.756 billion and adjusted earnings of $1.45 per share. Double-digit year-over-year growth was seen across all major segments, with Cardiovascular up 19.5%, Diabetes up 16.9%, Neuroscience up 10.3% and Medical Surgical up 10%, though an extra fiscal week added approximately $570 million to quarterly revenue. CFO Thierry Piéton said the Cardiac Ablation Solutions segment is annualizing at more than $2 billion in revenue, and the unit surpassed $2 billion in trailing 12-month revenue in Q1 FY27, ahead of management's target. The company made a $700 million strategic investment in Cornerstone Robotics that includes rights to distribute the Sentire Surgical System in select markets outside the US, complementing its existing Hugo robotic-assisted surgery system. Medtronic carries a market capitalization of almost $109.3 billion, with $37.54 billion in revenue over the prior twelve months, an operating margin of 19.33% and a net margin of 13.93%; the stock trades at a trailing price-to-earnings multiple of 22x and a forward P/E of 14.93x. Hedge fund holdings rose to 67 in the second quarter of 2026 from 60 in the prior quarter, while BlackRock is the largest institutional investor with 114.02 million shares, or 8.91% of outstanding shares.

Medtronic reported first-quarter fiscal 2027 revenue of $9.76 billion, up 13.7% from a year earlier, and raised its full-year outlook, with adjusted diluted EPS climbing 15.1% to $1.45 and GAAP EPS rising 40.7% to $1.14. Management now expects organic revenue growth of 7.25%-7.75% for fiscal 2027, up from 6.75%-7.25% previously, and lifted adjusted EPS guidance to $5.94-$6.00. The quarter included an extra selling week that added about $570 million to revenue, so the headline growth rate should not be expected to repeat. Cardiovascular delivered strong growth, while Neuroscience, Medical Surgical and Diabetes also posted high-single-digit or double-digit organic growth. At a share price of around $89-$90, the stock trades at roughly 15 times the midpoint of the adjusted EPS forecast, versus about 22 times trailing earnings, while paying a quarterly dividend of $0.72 per share, or $2.88 a year, for a yield of roughly 3.2%-3.3%. Medtronic is also expanding its Affera cardiac mapping and ablation system, investing in Pi-Cardia and Cornerstone Robotics, and has acquired Scientia Vascular and SPR Therapeutics, with a planned separation of its Diabetes business.

Neuromod Devices has announced the appointment of Joe Ghiz as Chief Commercial Officer and Shannon Basham as VP of Channel Development. Ghiz joins Neuromod's senior management team and will lead the company's global commercial function as it continues to strengthen its position as the category creator in tinnitus care, with CEO Dr. Ross O'Neill citing robust clinical evidence, global regulatory approval, and broad commercial adoption as positioning the company for rapid scaling to address the needs of 740 million tinnitus sufferers worldwide. Ghiz joins from Align Technology, the company behind Invisalign, where he helped create and scale the clear aligner category and built a $10 billion company, and previously spent over a decade at Johnson & Johnson Vision Care in leadership roles spanning sales, marketing, and business development. Basham brings more than 20 years of experience in the hearing care industry, having most recently served as Senior Director of Audiology for Sonova Group in the United States of America, where she was the market-facing head of audiology for the Phonak and Unitron wholesale businesses. The appointments support Neuromod's goal of positioning its non-invasive bimodal neuromodulation tinnitus treatment device, Lenire, as a new standard of care in ENT and audiology practices.

Onward Medical reported H1 2026 revenue of EUR4.2 million, up 250% year-over-year, with EUR3.4 million coming from product revenues and gross profit of EUR2.9 million at roughly 70% gross margin. The company sold or supplied 159 ARC-EX systems via paid evaluation in H1 2026, more than a 5x increase year-over-year, including 89 units sold in Q2 2026 alone, with the device now available in over 150 clinics worldwide, including over 130 in the US, covering an estimated 35-40% of US facilities managing spinal cord injury. Operating expenses rose to EUR26.3 million from EUR21 million in H1 2025, producing an operating loss of EUR23.3 million and a net loss of EUR24.7 million, while cash burn reached EUR26 million. The company ended June 2026 with EUR81.5 million in cash, up from EUR68.1 million at the start of the year, after raising over EUR40 million in new equity capital including EUR25 million from EQT Life Sciences, and secured a debt facility of up to EUR50 million from BlackRock replacing its existing loan, with EUR20 million drawn at closing, extending its cash runway into Q1 2028. On the clinical side, the EMPOWER-BP pivotal trial has enrolled 22 participants across 14 active sites, with interim analysis expected by end of Q1 or early Q2 2027, and the company completed its CMS coding submission with a decision expected in Q4 2026.